Central Bank & Trust Co. Sells 4,591 Shares of Novo Nordisk A/S (NYSE:NVO)

Central Bank & Trust Co. cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 14.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,087 shares of the company’s stock after selling 4,591 shares during the quarter. Central Bank & Trust Co.’s holdings in Novo Nordisk A/S were worth $2,330,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth about $25,000. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at approximately $28,000. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $42,000. Carolina Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the third quarter worth $48,000. Finally, M&R Capital Management Inc. boosted its position in shares of Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after acquiring an additional 297 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $78.74 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock’s fifty day moving average is $97.76 and its 200 day moving average is $116.89. The firm has a market capitalization of $353.33 billion, a PE ratio of 25.48, a PEG ratio of 0.84 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.